A broad panel of immunohistochemical markers was used to narrow down the differential diagnosis, which included epithelial origin cancers (MNF116), melanoma (S100, HMB-45, Melan-A), and rhabdomyosarcoma (myogenin). Here, PMEL is linked to cancer.